ロード中...
Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response
Early success with brentuximab vedotin in treating classical Hodgkin lymphoma spurred an influx of at least 20 monomethyl auristatin E (MMAE) antibody-drug conjugates (ADCs) into clinical trials. While three MMAE-ADCs have been approved, most of these conjugates are no longer being investigated in c...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis Group
2021-01-01
|
| シリーズ: | mAbs |
| 主題: | |
| オンライン･アクセス: | https://www.tandfonline.com/doi/10.1080/19420862.2020.1862452 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|